[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"The Binding Site Group, Ltd.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":100},{"warningLetters":4,"total":99},[5,31,53,76],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},2360,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-11-08T14:20:00Z\">11\u002F08\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-03T04:00:00Z\">11\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fanthos-group-inc-636846-11032022\">The Anthos Group, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Refusal to Provide Access to and Copying of Records","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Shan Umer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>The Anthos Group, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>705 N Douglas Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>El Segundo\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90245\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-23-03\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 3, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Umer:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products; specifically, products including VERTRA Hand Sanitizer. On December 4, 2020, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. After a second request was sent to your contact e-mail address, your firm responded stating that you had forwarded FDA’s request to the appropriate manufacturer. The Agency sent a follow-up written request for such records and other information by certified return-receipt mail on August 12, 2021 to the physical address provided in your registration file. The written request was returned after multiple delivery attempts. FDA attempted to contact you at the telephone number provided in your registration file regarding this matter which went unanswered. You failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\u003C\u002Fp>\n\n\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\u003C\u002Fp>\n\n\u003Cp>Since declaration of the COVID-19 public health emergency,\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> a number of hand sanitizer products have been recalled due to quality issues including substitution with other drug substances, impurities at unacceptable levels, and subpotency.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The Agency has reached out to registered OTC drug firms with hand sanitizers included in their product listing to assess the overall quality of the drugs registered as manufactured by these firms. Because your OTC drug firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\u003C\u002Fp>\n\n\u003Cp>Respond to this letter within 48 hours to confirm or update your registration and\u002For drug listing status and indicate whether you will respond to the request for records and other information. If you are no longer manufacturing drugs, delist all the drugs previously listed with FDA, using the last lot expiration date as the marketing end date of the product, and deregister your facility accordingly.\u003C\u002Fp>\n\n\u003Cp>The Agency may conduct an inspection to verify information provided and\u002For to evaluate the compliance of your manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>Continued non-response regarding questions of the quality assurance of the drugs manufactured at your facility may lead to inclusion on the Agency’s list of hand sanitizers consumers should not use, at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>You may provide additional information for our consideration as we continue to assess your activities and practices.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Identify your response with FEI 3016861323 and ATTN: Rory Geyer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research, FDA\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The HHS Declaration of a Public Health Emergency is available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> In March 2020, the Agency published three guidance documents to provide regulatory flexibility to certain firms to help meet the demand for alcohol-based hand sanitizer during the COVID-19 PHE. Additionally, on December 31, 2021, these guidances were withdrawn, and firms were required to cease distribution, by March 31, 2022, of any remaining hand sanitizer products that were prepared under the temporary policies before or on December 31, 2021. See, 86 FR 56960, October 13, 2021.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Shan Umer\n\nRecipient Title\n\nPresident\n\nThe Anthos Group, Inc.\n\n705 N Douglas Street\n\nEl Segundo, CA 90245\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-03\n\nNovember 3, 2022\n\nDear Mr. Umer:\n\nYour firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products; specifically, products including VERTRA Hand Sanitizer. On December 4, 2020, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. After a second request was sent to your contact e-mail address, your firm responded stating that you had forwarded FDA’s request to the appropriate manufacturer. The Agency sent a follow-up written request for such records and other information by certified return-receipt mail on August 12, 2021 to the physical address provided in your registration file. The written request was returned after multiple delivery attempts. FDA attempted to contact you at the telephone number provided in your registration file regarding this matter which went unanswered. You failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\n\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\n\nSince declaration of the COVID-19 public health emergency,1 a number of hand sanitizer products have been recalled due to quality issues including substitution with other drug substances, impurities at unacceptable levels, and subpotency.2 The Agency has reached out to registered OTC drug firms with hand sanitizers included in their product listing to assess the overall quality of the drugs registered as manufactured by these firms. Because your OTC drug firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\n\nRespond to this letter within 48 hours to confirm or update your registration and\u002For drug listing status and indicate whether you will respond to the request for records and other information. If you are no longer manufacturing drugs, delist all the drugs previously listed with FDA, using the last lot expiration date as the marketing end date of the product, and deregister your facility accordingly.\n\nThe Agency may conduct an inspection to verify information provided and\u002For to evaluate the compliance of your manufacturing operations.\n\nContinued non-response regarding questions of the quality assurance of the drugs manufactured at your facility may lead to inclusion on the Agency’s list of hand sanitizers consumers should not use, at: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.\n\nYou may provide additional information for our consideration as we continue to assess your activities and practices.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nIdentify your response with FEI 3016861323 and ATTN: Rory Geyer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research, FDA\n\n_____________________\n\n1 The HHS Declaration of a Public Health Emergency is available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx.\n\n2 In March 2020, the Agency published three guidance documents to provide regulatory flexibility to certain firms to help meet the demand for alcohol-based hand sanitizer during the COVID-19 PHE. Additionally, on December 31, 2021, these guidances were withdrawn, and firms were required to cease distribution, by March 31, 2022, of any remaining hand sanitizer products that were prepared under the temporary policies before or on December 31, 2021. See, 86 FR 56960, October 13, 2021.","The Anthos Group, Inc.","anthos-group-inc-636846-11032022","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fanthos-group-inc-636846-11032022","2026-10-26T08:07:56.187809+00:00","Warning Letter","Issued","2022-11-08","636846","Drugs","Mr. Shan Umer","2026-08-20T01:27:21.953+00:00","VIA UPS","2022-11-03",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},206,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2026-04-28T04:00:00Z\">04\u002F28\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-08T04:00:00Z\">04\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwilatta-group-inc-727025-04082026\">The Wilatta Group Inc.\u003C\u002Fa>","Office of Inspections and Investigations","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Eugene Krofah\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner and General Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>The Wilatta Group Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10310 Pond Spice Ter.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Burke\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>22015-3739\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ekrofah@wilatta.com\"> ekrofah@wilatta.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>RE: CMS# 727025\u003C\u002Fp>\u003Cp>Dear Mr. Krofah,\u003C\u002Fp>\u003Cp>On March 10, 2026, through March 18, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of The Wilatta Group Inc located at 10310 Pond Spice Ter, Burke, VA 22015-3739. We also conducted inspections from September 18, 2022, through September 23, 2022, and September 17, 2019, through September 24, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on March 18, 2026.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cul>\u003Cli>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003Cbr>o Melon seeds, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>o Condensed milk powder, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>o Chocolate spread, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata. fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Stanley Nelson, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Stanley. Nelson@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Nelson via email at Stanley.Nelson@fda.hhs.gov. Please reference CMS # 727025 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CDR Joseph S. Tomao\u003Cbr>Program Division Director\u003Cbr>Division of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nEugene Krofah\n\nRecipient Title\n\nOwner and General Manager\n\nThe Wilatta Group Inc.\n\n10310 Pond Spice Ter.\n\nBurke, VA 22015-3739\n\nUnited States\n\nekrofah@wilatta.com\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nWARNING LETTER\nRE: CMS# 727025\nDear Mr. Krofah,\nOn March 10, 2026, through March 18, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of The Wilatta Group Inc located at 10310 Pond Spice Ter, Burke, VA 22015-3739. We also conducted inspections from September 18, 2022, through September 23, 2022, and September 17, 2019, through September 24, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on March 18, 2026.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\no Melon seeds, imported from (b)(4), located in (b)(4).\no Condensed milk powder, imported from (b)(4), located in (b)(4).\no Chocolate spread, imported from (b)(4), located in (b)(4).\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata. fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Stanley Nelson, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Stanley. Nelson@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Nelson via email at Stanley.Nelson@fda.hhs.gov. Please reference CMS # 727025 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nCDR Joseph S. Tomao\nProgram Division Director\nDivision of Northeast Imports","The Wilatta Group Inc.","wilatta-group-inc-727025-04082026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwilatta-group-inc-727025-04082026","2026-10-26T08:10:31.938224+00:00","2026-04-28","727025","Food & Beverages","Eugene Krofah","2026-08-19T04:45:57.687+00:00","Via Email","2026-04-08",{"id":54,"raw":55,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":70,"closeout_date":19,"issuing_office":59,"recipient_name":71,"body_fetched_at":72,"delivery_method":73,"recipient_title":19,"reference_number":74,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},1379,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2024-07-16T13:20:00Z\">07\u002F16\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-05T04:00:00Z\">07\u002F05\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Febs-trading-group-llc-687777-07052024\">EBS Trading Group LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2402171\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Sagi Isaschar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>EBS Trading Group LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3701 N Country Club Dr\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Aventura\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33180\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@thevapersworld.com\"> sales@thevapersworld.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@new.thevapersworld.com\"> sales@new.thevapersworld.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Sagi Isaschar:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fthevapersworld.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. &nbsp;Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. &nbsp;See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. &nbsp;Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. &nbsp;For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. &nbsp;A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). &nbsp;Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: Elf Bar Vape Disposable BC5000 – Crazi Berry and Lost Mary BM5000 Disposable Vape Device 3% Nic – Cranberry Soda.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. &nbsp;These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. &nbsp;Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). &nbsp;In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. &nbsp;All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.&nbsp;\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. &nbsp;Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. &nbsp;However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. &nbsp;Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. &nbsp;You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. &nbsp;If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. &nbsp;This letter notifies you of our findings and provides you with an opportunity to address them. &nbsp;You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2402171, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nJohn E. Verbeten\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement&nbsp;\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nVIA Electronic Mail\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com&nbsp;\u003C\u002Fp>\n\n\u003Cp>Hostinger International Limited\u003Cbr>\nabuse@hostinger.com&nbsp;\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS and Electronic Mail\n\nReference #:\n\nRW2402171\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nSagi Isaschar\n\nEBS Trading Group LLC\n\n3701 N Country Club Dr\n\nAventura, FL 33180\n\nUnited States\n\n(b)(6)\n\nsales@thevapersworld.com\n\nsales@new.thevapersworld.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Sagi Isaschar:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fthevapersworld.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: Elf Bar Vape Disposable BC5000 – Crazi Berry and Lost Mary BM5000 Disposable Vape Device 3% Nic – Cranberry Soda.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2402171, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJohn E. Verbeten\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA Electronic Mail\n\ncc:\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nHostinger International Limited\n\nabuse@hostinger.com","EBS Trading Group LLC","ebs-trading-group-llc-687777-07052024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Febs-trading-group-llc-687777-07052024","2026-10-26T08:08:30.452437+00:00","2024-07-16","687777","Tobacco","Sagi Isaschar","2026-08-19T23:58:05.685+00:00","UPS and Electronic Mail","RW2402171","2024-07-05",{"id":77,"raw":78,"subject":84,"body_html":85,"body_text":86,"firm_name":87,"letter_id":88,"created_at":89,"fei_number":19,"letter_url":90,"updated_at":91,"action_type":22,"case_status":23,"posted_date":92,"marcs_cms_no":93,"product_type":94,"closeout_date":19,"issuing_office":82,"recipient_name":95,"body_fetched_at":96,"delivery_method":97,"recipient_title":19,"reference_number":19,"action_taken_date":98,"medical_device_id":19,"response_letter_date":19},580,[79,80,81,82,83,13,13,13],"\u003Ctime datetime=\"2025-09-23T04:00:00Z\">09\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-25T04:00:00Z\">08\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frichline-group-inc-712818-08252025\">The Richline Group, Inc. \u003C\u002Fa>","Center for Devices and Radiological Health","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)\u003Cbr \u002F>\r\n","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David E. Radcliffe\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Information Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>The Richline Group, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6701 Nob Hill Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tamarac\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33321-6402\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:David.Radcliffe@richlinegroup.com\"> David.Radcliffe@richlinegroup.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 712818\u003C\u002Fp>\u003Cp>August 25, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Radcliffe:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Tamarac, FL, from March 24, 2025, through April 16, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Inverness Ear Care Antiseptic, Inverness Ear Care Solution, and Inverness Home Ear Piercing Kit products. The inspection of your firm identified violations of the Food, Drug, and Cosmetic Act, a number of which were repeat violations from an earlier inspection. We note that FDA has had prior communications with your firm about these products.\u003C\u002Fp>\u003Cp>Our inspection and review of the available information revealed that your firm markets the Inverness Ear Care Antiseptic and Inverness Ear Care Solution without marketing authorization. Wound washes containing certain chemicals, including antimicrobials (e.g., benzalkonium chloride), include several risks which necessitate the premarket review of these products prior to marketing. These risks include adverse tissue reaction, toxicity, delayed wound healing, incompatibilities with other therapies, contribution to the spread of antimicrobial resistance, infection, microbial growth within the product, product degradation during stated shelf storage, and negatively impacting the skin microbiota in the periwound area resulting in impaired wound healing. Wound washes with certain chemicals, such as antimicrobials for preservative purposes only, that are intended to irrigate a wound are generally regulated by the Center for Devices and Radiological Health (CDRH), categorized within FDA product code FRO (dressing, wound, drug), and require submission of a 510(k) for FDA review. However, please note that the claims and indications for a product can impact the regulatory pathway of the product, as well as the classification or jurisdiction of the product. Your firm appears to be making claims that go beyond the types of claims appropriate for wound washes categorized under the FRO product code. For example, the current labeling for Ear Care Antiseptic suggests that the benzalkonium chloride component is intended for use as an antiseptic rather than a preservative. The Ear Care Antiseptic labeling identifies benzalkonium chloride as the active ingredient, for the purpose of ear care antiseptic, e.g., as identified in the name of the product. If you intend to continue making such claims, we note that your products may be regulated by the Center for Drug Evaluation and Research (CDER) and require an approved new drug application, among other requirements.\u003C\u002Fp>\u003Cp>However, assuming that the claims for these products would be consistent with wound care products regulated by CDRH, these products would be adulterated under section 501(f)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products would also be misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the products into interstate commerce for commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a product requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency (21 CFR 807.81(b)). The kind of information that your firm needs to submit in order to obtain approval or clearance for the products is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\u003C\u002Fp>\u003Cp>Additionally, assuming that the claims for these products would be consistent with wound care products regulated by CDRH, your products would be in violation of the Act in other respects as well, as discussed further below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on this inspection, your products would be adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from Mr. Jose A. Abrams, Jr., Director of Quality Assurance dated May 5, 2025, and June 18, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\u003C\u002Fp>\u003Cp>For example: Your firm has not implemented design controls for your products, including the Inverness Home Ear Piercing Kits, Ear Care Antiseptic, and Ear Care Solution. Specifically:\u003C\u002Fp>\u003Cp>a. Your firm defines requirements in your Design Control procedure, SOP-003, Ver. 0, 10\u002F10\u002F2024 for design and development planning, design input, design output, design verification, design validation, design transfer, design review, and design history for your products, but does not maintain design documents that support these established requirements, including any documentation of design control requirements from the original design of the products. During the inspection, these records were requested, and your Quality Control Manager affirmed that your firm has not established any design controls or developed design plans for your firm’s products. Accordingly, your firm has been operating without design controls since \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>b. Your firm has not addressed expiration dating as part of the design controls. Although your firm’s Ear Care Antiseptic &amp; Ear Care Solution Preparation procedure, SOP-015, Ver. 0, 01\u002F16\u002F2025, requires each bottle of Ear Care Antiseptic and Ear Care Solution to be printed with an expiration date \u003Cstrong>(b)(4)\u003C\u002Fstrong> beyond the batch mixing date, your firm maintains no supporting documentation for the current \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date of such products, or for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date of your sterile cassette containing 2-piercing cartridges. Your firm provided the report, Technique Report Ref: 1330084, Accelerated Stability Trial (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), to demonstrate testing was conducted on the Ear Care Solution in \u003Cstrong>(b)(4)\u003C\u002Fstrong> but the report does not include: Testing protocol, actual testing raw data, product packaging configuration, and batch\u002Flot number, in support of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date for the firm’s Ear Care Solution and Ear Care Antiseptic. Also, your firm maintains no supporting documentation for testing conducted for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date for your firm’s sterile cassette.\u003C\u002Fp>\u003Cp>Your firm manufactured and distributed over \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles of Ear Care Antiseptic and Ear Care Solution, configured in 2 oz., 4 oz., and 16 oz. bottle sizes, for your Home Ear Piercing Kits and for individual own-label and private-label sale, between June 2024 and April 2025, without proper design controls in place.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm's response (CAPA-25-004) is inadequate because it provides only partial coverage of the design control violations and lacks implementation specifics. While the CAPA acknowledges the need for design controls, it does not comprehensively address all identified deficiencies and fails to detail how each aspect of the design control process will be implemented. Critically, your response lacks a documented plan for establishing and validating product expiration dates and does not explain how compliance with SOP-003 (Design Control) will be ensured across all design process elements for your products.\u003C\u002Fp>\u003Cp>Additionally, the ongoing status of CAPA-25-004, which has been extended \u003Cstrong>(b)(4)\u003C\u002Fstrong> per CAPA-EXT-002, raises concerns about your firm's ability to effectively implement necessary corrections. Your firm’s CAPA-25-004 should be revised to comprehensively address this design control violation, including specific implementation plans for each design control element; establish clear procedures for expiration date documentation and validation; and demonstrate how SOP-003 compliance will be achieved and maintained throughout your design processes.\u003C\u002Fp>\u003Cp>2. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure. The validation activities and results, including the date and signature of the individual(s) approving the validation and where appropriate the major equipment validated, are to be documented, as required by 21 CFR 820.75(a).\u003C\u002Fp>\u003Cp>For example: Your firm has not validated the manufacturing process and equipment used to produce Inverness Ear Care Solution and Ear Care Antiseptic. Your firm has defined requirements for validations in your procedure, Production and Process Control, SOP-021, Ver. 0, 09\u002F05\u002F2024, but does not maintain documents that address original process validations and any subsequent re-validations, to ensure that robust, reliable, and efficiently monitored processes are used to manufacture product. Specifically:\u003C\u002Fp>\u003Cp>a. Equipment used to establish and to monitor critical parameters such as tank fill weight, water quality, raw material weight, mixing speed, and mixing times is not validated.\u003C\u002Fp>\u003Cp>b. Your firm’s procedure, SOP-021, requires determination of process variables and that they be understood and controlled through validation, e.g., batch size. However, three different batch sizes of Ear Care Antiseptic Batch (Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> lbs., Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> lbs., and Lot#\u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> lbs.) were produced without establishing critical process parameters through validation for each batch size, to consistently meet predetermined specifications.\u003C\u002Fp>\u003Cp>c. Critical equipment used in the manufacture of your firm’s products, including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is not validated. This is not consistent with your firm’s procedure, SOP-021, which requires the documentation and validation of products and equipment transferred in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> relocation from Massachusetts to the current facility in Florida.\u003C\u002Fp>\u003Cp>d. Validation protocol and\u002For validation report is not maintained by your firm for your manufactured products.\u003C\u002Fp>\u003Cp>Your firm manufactured and distributed over \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles of Ear Care Antiseptic and Ear Care Solution, configured in 2 oz., 4 oz., and 16 oz. bottle sizes, for your Home Ear Piercing Kits and for individual own-label and private-label sale, between June 2024 and April 2025, without proper equipment and process validations in place. This is a continued and repeated violation from the previous inspection of your firm’s facility.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm's response (CAPA-25-007) is inadequate because it lacks specificity and essential documentation. While the CAPA addresses general validation concerns, it fails to specify how critical process parameters, manufacturing equipment (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4) \u003C\u002Fstrong>the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system, and different batch sizes will be validated.\u003C\u002Fp>\u003Cp>Additionally, your response does not include required supporting documentation such as validation protocols, validation summary reports, equipment qualification documentation, or batch size validation studies. The implementation status remains unclear, as you have not indicated whether proposed corrective actions have been implemented, provided implementation timelines, nor described interim measures during CAPA execution.\u003C\u002Fp>\u003Cp>Furthermore, your CAPA inadequately addresses the repeat nature of this validation deficiency, which typically requires more comprehensive corrective actions than those proposed. While training is mentioned, the response lacks concrete validation methodologies and procedures necessary to ensure process control and product quality. The focus on training alone does not substitute for the development and implementation of actual validation processes. Your firm’s response should include a revised CAPA that includes specific validation protocols with supporting documentation, clear implementation timelines, and comprehensive measures to prevent recurrence of these validation deficiencies.\u003C\u002Fp>\u003Cp>3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a).\u003C\u002Fp>\u003Cp>For example: Your firm has not implemented your \u003Cstrong>(b)(4)\u003C\u002Fstrong> System procedure, SOP-034, Ver. 0, 01\u002F16\u002F2025, to maintain records for the conduct of required \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Records requested during the inspection for eight \u003Cstrong>(b)(4)\u003C\u002Fstrong> of monitoring show your firm did not maintain water monitoring records for three of the eight \u003Cstrong>(b)(4)\u003C\u002Fstrong> in January, February, and March 2025, which is not consistent with the requirements of your procedure. Five \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring records in January, February, March, and April 2025, reviewed during the inspection, similarly showed \u003Cstrong>(b)(4) \u003C\u002Fstrong>weekly monitoring records are incomplete, where \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring is not recorded as required by procedure.\u003C\u002Fp>\u003Cp>Your Quality Control Manager stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm has not demonstrated that this sampling plan adequately represents the microbiological quality of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring and is sufficient to detect microbial contamination. Additionally, your procedure SOP-034 lacks essential requirements including testing frequency, sample quantities, identification of viable organisms in the manufacturing process, and microbial count action levels. This is a continued and repeated violation from the previous inspection of your firm’s facility.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. While CAPA-25-004 was initiated to address \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring and records were provided demonstrating \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring activities, the response fails to identify the root cause of previous monitoring failures or provide a comprehensive plan to prevent recurrence. Your firm attributes the issue to training deficiencies but does not explain why training was inadequate or demonstrate that additional training will effectively address the underlying problem.\u003C\u002Fp>\u003Cp>Your firm’s response should provide for establishing microbiological sampling requirements at appropriate frequencies, update SOP-034 to include comprehensive monitoring requirements (the current version remains unchanged from the inspection and still lacks microbiological testing requirements), ensure consistent performance and documentation of all required monitoring, and address the recurring nature of this observation with more urgent corrective actions. CAPA-25-004 remains ongoing and has been extended 60 days per CAPA-EXT-002, as of your June 18, 2025, response.\u003C\u002Fp>\u003Cp>4. Failure to validate computer software for its intended use according to an established protocol when computers or automated data processing systems are used as part of production or the quality system, as required by 21 CFR 820.70(i).\u003C\u002Fp>\u003Cp>For example: Your firm has not validated the Excel spreadsheet for its intended use of calculating the final concentration of benzalkonium chloride in your manufactured, finished products, Inverness Ear Care Solution (0.09%) and Inverness Ear Care Antiseptic (0.12%). Not validating the formulation software for each different batch size can result in super-potent or sub-potent finished products that may present a risk to health for the users of the product, including adverse tissue reactions, immunological reactions, transmission of pathogens and parasites, toxicity, delayed wound healing, infection, microbial growth or product degradation during storage, and inability to remove wound debris and foreign materials. Scaling batch size up or down can have an intrinsic effect on the finished product chemical and physical properties. This is a continued and repeated deficiency from previous inspection of your firm’s facility.\u003C\u002Fp>\u003Cp>The adequacy of your firm's response cannot be determined at this time. While CAPA-25-007 was provided to include Excel Validation Protocol (TP-25-001) and Excel Validation Report (TP-25-001-TR) under SOP-021-B, to address the Excel software and formula spreadsheet, your response is incomplete. Although the Excel Validation Report demonstrates that your firm initiated software validation of the Excel formula spreadsheet, you have not provided confirmatory testing (assay) data to verify that the Inverness Ear Care Solution (0.09%) and Inverness Ear Care Antiseptic (0.12%) products manufactured using the newly validated Excel formula spreadsheet meet the established specifications outlined in SOP-021-B, Section 2, Product Characteristics.\u003C\u002Fp>\u003Cp>5. Failure to ensure that all inspection, measuring, and test equipment, including mechanical, automated, or electronic inspection and test equipment, is suitable for its intended purposes and is capable of producing valid results, as required by 21 CFR 820.72(a).\u003C\u002Fp>\u003Cp>For example: Your firm has not adequately implemented SOP-017 (Control of Measuring and Monitoring Devices, Ver. 0, 09\u002F05\u002F2024) to ensure scales used for weighing water in mixing Tanks C and D are calibrated within the appropriate working range. The last \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of Ear Care Solution produced in these tanks had a final batch size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> lbs., yet calibration records show the scales were only calibrated for a weight range of \u003Cstrong>(b)(4)\u003C\u002Fstrong> lbs. This inadequate calibration range may result in super-potent or sub-potent finished products, presenting health risks to users.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. While CAPA-25-008 was provided to address scale calibration for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> under SOP-017, and your firm acknowledges the importance of ensuring correct calibration ranges for tank weights, you have not provided evidence that the scales are calibrated within the batch size working range. Your firm’s response also lacks a documented rationale demonstrating that calibrating the scales for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> up to only \u003Cstrong>(b)(4)\u003C\u002Fstrong> lbs. is acceptable for \u003Cstrong>(b)(4)\u003C\u002Fstrong> lb. batches. It is also concerning that your firm did not evaluate the potential that the use of the scale outside the calibrated range could have resulted in distribution of nonconforming product. The response merely states that calibration certificates were located, and calibration status was confirmed for all equipment, without addressing the fundamental calibration range deficiency.\u003C\u002Fp>\u003Cp>6. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\u003C\u002Fp>\u003Cp>For example: During the investigator’s walk-through of your firm’s finished-goods, inventory area, multiple examples of non-conforming product, i.e., mis-labeled, non-labeled, expired, and leaking products were observed held for sale and ready for shipment to customers. Your firm failed to implement your Control of Nonconformances procedure, SOP-022, to properly quarantine and control the affected products because your firm has no identified and dedicated quarantine area to segregate and maintain nonconforming product from finished product inventory for determining product final disposition.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. CAPA-25-009 was provided to address control of non-conforming product. While this CAPA acknowledges the lack of a quarantine area and product non-conformance issues and proposes establishing a dedicated quarantine area with personnel retraining on SOP-022 (Control of Nonconformances), it lacks essential elements including specific corrective actions for each non-conformance type (i.e., unlabeled bottles, expired products, incorrect components, leaking bottles), preventive measures to avoid recurrence, and how ongoing compliance with SOP-022 will be ensured, including specific actions for implementing and maintaining the quarantine area, and establishing a plan for measuring corrective action effectiveness.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>UDI Labeling\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection revealed that your products would be misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the products was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and package bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Inverness Home Ear Piercing Kit, Inverness Ear Care Solution (0.09%), and Inverness Ear Care Antiseptic (0.12%) products do not bear such a UDI.\u003C\u002Fp>\u003Cp>Specifically, the labels for the Inverness Home Ear Piercing Kit, Inverness Ear Care Solution (0.09%), and Inverness Ear Care Antiseptic (0.12%) products do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology on the label (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm provided CAPA-25-014, which promises to establish UDIs and update all labels by June 13, 2025. In addition, your firm provided evidence of acquiring DIs for Ear Care Solution, Ear Care Antiseptic, Inverness Disposable Nose Piercing Instrument, and Inverness Reusable Ear Piercing Instruct from GS1. However, your firm has not provided information about the design of the new labels and examples that include valid UDIs.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Submitting Required Information to GUDID\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, the Inverness Home Ear Piercing Kit, Inverness Ear Care Solution (0.09%), and Inverness Ear Care Antiseptic (0.12%) products are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these products. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to these products with the intent that they be commercially distributed without any subsequent replacement or modification of the label. Richline Group, Inc. is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these products.\u003C\u002Fp>\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Though CAPA-25-014 mentions FDA 483 Observation 16 regarding GUDID reporting, the analysis, root cause, and solution do not address the need for GUDID reporting.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We recommend that your firm establish an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports, so that your firm can comply with 21 CFR 803.12(a). FDA verified that, as of June 11, 2025, your firm does not have such an account. Information about the ESG can be found at: How to Enroll in eMDR Program | FDA\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your products or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Assistant Director, at CDRHEnforcement@fda.hhs.gov. Refer to CMS # 712818 when replying. If you have any questions about the contents of this letter, please contact Salvatore Randazzo, Compliance Officer, at 407-475-4712 or salvatore.randazzo@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDavid E. Radcliffe\n\nRecipient Title\n\nChief Information Officer\n\nThe Richline Group, Inc.\n\n6701 Nob Hill Road\n\nTamarac, FL 33321-6402\n\nUnited States\n\nDavid.Radcliffe@richlinegroup.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 712818\nAugust 25, 2025\nDear Mr. Radcliffe:\nDuring an inspection of your firm located in Tamarac, FL, from March 24, 2025, through April 16, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Inverness Ear Care Antiseptic, Inverness Ear Care Solution, and Inverness Home Ear Piercing Kit products. The inspection of your firm identified violations of the Food, Drug, and Cosmetic Act, a number of which were repeat violations from an earlier inspection. We note that FDA has had prior communications with your firm about these products.\nOur inspection and review of the available information revealed that your firm markets the Inverness Ear Care Antiseptic and Inverness Ear Care Solution without marketing authorization. Wound washes containing certain chemicals, including antimicrobials (e.g., benzalkonium chloride), include several risks which necessitate the premarket review of these products prior to marketing. These risks include adverse tissue reaction, toxicity, delayed wound healing, incompatibilities with other therapies, contribution to the spread of antimicrobial resistance, infection, microbial growth within the product, product degradation during stated shelf storage, and negatively impacting the skin microbiota in the periwound area resulting in impaired wound healing. Wound washes with certain chemicals, such as antimicrobials for preservative purposes only, that are intended to irrigate a wound are generally regulated by the Center for Devices and Radiological Health (CDRH), categorized within FDA product code FRO (dressing, wound, drug), and require submission of a 510(k) for FDA review. However, please note that the claims and indications for a product can impact the regulatory pathway of the product, as well as the classification or jurisdiction of the product. Your firm appears to be making claims that go beyond the types of claims appropriate for wound washes categorized under the FRO product code. For example, the current labeling for Ear Care Antiseptic suggests that the benzalkonium chloride component is intended for use as an antiseptic rather than a preservative. The Ear Care Antiseptic labeling identifies benzalkonium chloride as the active ingredient, for the purpose of ear care antiseptic, e.g., as identified in the name of the product. If you intend to continue making such claims, we note that your products may be regulated by the Center for Drug Evaluation and Research (CDER) and require an approved new drug application, among other requirements.\nHowever, assuming that the claims for these products would be consistent with wound care products regulated by CDRH, these products would be adulterated under section 501(f)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products would also be misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the products into interstate commerce for commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a product requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency (21 CFR 807.81(b)). The kind of information that your firm needs to submit in order to obtain approval or clearance for the products is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\nAdditionally, assuming that the claims for these products would be consistent with wound care products regulated by CDRH, your products would be in violation of the Act in other respects as well, as discussed further below.\nQuality System Regulation\nBased on this inspection, your products would be adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from Mr. Jose A. Abrams, Jr., Director of Quality Assurance dated May 5, 2025, and June 18, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\nFor example: Your firm has not implemented design controls for your products, including the Inverness Home Ear Piercing Kits, Ear Care Antiseptic, and Ear Care Solution. Specifically:\na. Your firm defines requirements in your Design Control procedure, SOP-003, Ver. 0, 10\u002F10\u002F2024 for design and development planning, design input, design output, design verification, design validation, design transfer, design review, and design history for your products, but does not maintain design documents that support these established requirements, including any documentation of design control requirements from the original design of the products. During the inspection, these records were requested, and your Quality Control Manager affirmed that your firm has not established any design controls or developed design plans for your firm’s products. Accordingly, your firm has been operating without design controls since (b)(4).\nb. Your firm has not addressed expiration dating as part of the design controls. Although your firm’s Ear Care Antiseptic & Ear Care Solution Preparation procedure, SOP-015, Ver. 0, 01\u002F16\u002F2025, requires each bottle of Ear Care Antiseptic and Ear Care Solution to be printed with an expiration date (b)(4) beyond the batch mixing date, your firm maintains no supporting documentation for the current (b)(4) expiration date of such products, or for the (b)(4) expiration date of your sterile cassette containing 2-piercing cartridges. Your firm provided the report, Technique Report Ref: 1330084, Accelerated Stability Trial ((b)(4)), to demonstrate testing was conducted on the Ear Care Solution in (b)(4) but the report does not include: Testing protocol, actual testing raw data, product packaging configuration, and batch\u002Flot number, in support of the (b)(4) expiration date for the firm’s Ear Care Solution and Ear Care Antiseptic. Also, your firm maintains no supporting documentation for testing conducted for the (b)(4) expiration date for your firm’s sterile cassette.\nYour firm manufactured and distributed over (b)(4) bottles of Ear Care Antiseptic and Ear Care Solution, configured in 2 oz., 4 oz., and 16 oz. bottle sizes, for your Home Ear Piercing Kits and for individual own-label and private-label sale, between June 2024 and April 2025, without proper design controls in place.\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm's response (CAPA-25-004) is inadequate because it provides only partial coverage of the design control violations and lacks implementation specifics. While the CAPA acknowledges the need for design controls, it does not comprehensively address all identified deficiencies and fails to detail how each aspect of the design control process will be implemented. Critically, your response lacks a documented plan for establishing and validating product expiration dates and does not explain how compliance with SOP-003 (Design Control) will be ensured across all design process elements for your products.\nAdditionally, the ongoing status of CAPA-25-004, which has been extended (b)(4) per CAPA-EXT-002, raises concerns about your firm's ability to effectively implement necessary corrections. Your firm’s CAPA-25-004 should be revised to comprehensively address this design control violation, including specific implementation plans for each design control element; establish clear procedures for expiration date documentation and validation; and demonstrate how SOP-003 compliance will be achieved and maintained throughout your design processes.\n2. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure. The validation activities and results, including the date and signature of the individual(s) approving the validation and where appropriate the major equipment validated, are to be documented, as required by 21 CFR 820.75(a).\nFor example: Your firm has not validated the manufacturing process and equipment used to produce Inverness Ear Care Solution and Ear Care Antiseptic. Your firm has defined requirements for validations in your procedure, Production and Process Control, SOP-021, Ver. 0, 09\u002F05\u002F2024, but does not maintain documents that address original process validations and any subsequent re-validations, to ensure that robust, reliable, and efficiently monitored processes are used to manufacture product. Specifically:\na. Equipment used to establish and to monitor critical parameters such as tank fill weight, water quality, raw material weight, mixing speed, and mixing times is not validated.\nb. Your firm’s procedure, SOP-021, requires determination of process variables and that they be understood and controlled through validation, e.g., batch size. However, three different batch sizes of Ear Care Antiseptic Batch (Lot #(b)(4) at (b)(4) lbs., Lot #(b)(4) at (b)(4) lbs., and Lot#(b)(4) at (b)(4) lbs.) were produced without establishing critical process parameters through validation for each batch size, to consistently meet predetermined specifications.\nc. Critical equipment used in the manufacture of your firm’s products, including the (b)(4) system, (b)(4), and (b)(4), is not validated. This is not consistent with your firm’s procedure, SOP-021, which requires the documentation and validation of products and equipment transferred in the (b)(4) relocation from Massachusetts to the current facility in Florida.\nd. Validation protocol and\u002For validation report is not maintained by your firm for your manufactured products.\nYour firm manufactured and distributed over (b)(4) bottles of Ear Care Antiseptic and Ear Care Solution, configured in 2 oz., 4 oz., and 16 oz. bottle sizes, for your Home Ear Piercing Kits and for individual own-label and private-label sale, between June 2024 and April 2025, without proper equipment and process validations in place. This is a continued and repeated violation from the previous inspection of your firm’s facility.\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm's response (CAPA-25-007) is inadequate because it lacks specificity and essential documentation. While the CAPA addresses general validation concerns, it fails to specify how critical process parameters, manufacturing equipment ((b)(4)), (b)(4), (b)(4) the (b)(4) system, and different batch sizes will be validated.\nAdditionally, your response does not include required supporting documentation such as validation protocols, validation summary reports, equipment qualification documentation, or batch size validation studies. The implementation status remains unclear, as you have not indicated whether proposed corrective actions have been implemented, provided implementation timelines, nor described interim measures during CAPA execution.\nFurthermore, your CAPA inadequately addresses the repeat nature of this validation deficiency, which typically requires more comprehensive corrective actions than those proposed. While training is mentioned, the response lacks concrete validation methodologies and procedures necessary to ensure process control and product quality. The focus on training alone does not substitute for the development and implementation of actual validation processes. Your firm’s response should include a revised CAPA that includes specific validation protocols with supporting documentation, clear implementation timelines, and comprehensive measures to prevent recurrence of these validation deficiencies.\n3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a).\nFor example: Your firm has not implemented your (b)(4) System procedure, SOP-034, Ver. 0, 01\u002F16\u002F2025, to maintain records for the conduct of required (b)(4) and (b)(4) monitoring of your (b)(4) system. Records requested during the inspection for eight (b)(4) of monitoring show your firm did not maintain water monitoring records for three of the eight (b)(4) in January, February, and March 2025, which is not consistent with the requirements of your procedure. Five (b)(4) monitoring records in January, February, March, and April 2025, reviewed during the inspection, similarly showed (b)(4) weekly monitoring records are incomplete, where (b)(4) monitoring is not recorded as required by procedure.\nYour Quality Control Manager stated that (b)(4). However, your firm has not demonstrated that this sampling plan adequately represents the microbiological quality of your (b)(4) system monitoring and is sufficient to detect microbial contamination. Additionally, your procedure SOP-034 lacks essential requirements including testing frequency, sample quantities, identification of viable organisms in the manufacturing process, and microbial count action levels. This is a continued and repeated violation from the previous inspection of your firm’s facility.\nWe reviewed your firm’s response and concluded that it is not adequate. While CAPA-25-004 was initiated to address (b)(4) system monitoring and records were provided demonstrating (b)(4) and (b)(4) monitoring activities, the response fails to identify the root cause of previous monitoring failures or provide a comprehensive plan to prevent recurrence. Your firm attributes the issue to training deficiencies but does not explain why training was inadequate or demonstrate that additional training will effectively address the underlying problem.\nYour firm’s response should provide for establishing microbiological sampling requirements at appropriate frequencies, update SOP-034 to include comprehensive monitoring requirements (the current version remains unchanged from the inspection and still lacks microbiological testing requirements), ensure consistent performance and documentation of all required monitoring, and address the recurring nature of this observation with more urgent corrective actions. CAPA-25-004 remains ongoing and has been extended 60 days per CAPA-EXT-002, as of your June 18, 2025, response.\n4. Failure to validate computer software for its intended use according to an established protocol when computers or automated data processing systems are used as part of production or the quality system, as required by 21 CFR 820.70(i).\nFor example: Your firm has not validated the Excel spreadsheet for its intended use of calculating the final concentration of benzalkonium chloride in your manufactured, finished products, Inverness Ear Care Solution (0.09%) and Inverness Ear Care Antiseptic (0.12%). Not validating the formulation software for each different batch size can result in super-potent or sub-potent finished products that may present a risk to health for the users of the product, including adverse tissue reactions, immunological reactions, transmission of pathogens and parasites, toxicity, delayed wound healing, infection, microbial growth or product degradation during storage, and inability to remove wound debris and foreign materials. Scaling batch size up or down can have an intrinsic effect on the finished product chemical and physical properties. This is a continued and repeated deficiency from previous inspection of your firm’s facility.\nThe adequacy of your firm's response cannot be determined at this time. While CAPA-25-007 was provided to include Excel Validation Protocol (TP-25-001) and Excel Validation Report (TP-25-001-TR) under SOP-021-B, to address the Excel software and formula spreadsheet, your response is incomplete. Although the Excel Validation Report demonstrates that your firm initiated software validation of the Excel formula spreadsheet, you have not provided confirmatory testing (assay) data to verify that the Inverness Ear Care Solution (0.09%) and Inverness Ear Care Antiseptic (0.12%) products manufactured using the newly validated Excel formula spreadsheet meet the established specifications outlined in SOP-021-B, Section 2, Product Characteristics.\n5. Failure to ensure that all inspection, measuring, and test equipment, including mechanical, automated, or electronic inspection and test equipment, is suitable for its intended purposes and is capable of producing valid results, as required by 21 CFR 820.72(a).\nFor example: Your firm has not adequately implemented SOP-017 (Control of Measuring and Monitoring Devices, Ver. 0, 09\u002F05\u002F2024) to ensure scales used for weighing water in mixing Tanks C and D are calibrated within the appropriate working range. The last (b)(4) batches of Ear Care Solution produced in these tanks had a final batch size of (b)(4) lbs., yet calibration records show the scales were only calibrated for a weight range of (b)(4) lbs. This inadequate calibration range may result in super-potent or sub-potent finished products, presenting health risks to users.\nWe reviewed your firm’s response and concluded that it is not adequate. While CAPA-25-008 was provided to address scale calibration for (b)(4) and (b)(4) under SOP-017, and your firm acknowledges the importance of ensuring correct calibration ranges for tank weights, you have not provided evidence that the scales are calibrated within the batch size working range. Your firm’s response also lacks a documented rationale demonstrating that calibrating the scales for (b)(4) and (b)(4) up to only (b)(4) lbs. is acceptable for (b)(4) lb. batches. It is also concerning that your firm did not evaluate the potential that the use of the scale outside the calibrated range could have resulted in distribution of nonconforming product. The response merely states that calibration certificates were located, and calibration status was confirmed for all equipment, without addressing the fundamental calibration range deficiency.\n6. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\nFor example: During the investigator’s walk-through of your firm’s finished-goods, inventory area, multiple examples of non-conforming product, i.e., mis-labeled, non-labeled, expired, and leaking products were observed held for sale and ready for shipment to customers. Your firm failed to implement your Control of Nonconformances procedure, SOP-022, to properly quarantine and control the affected products because your firm has no identified and dedicated quarantine area to segregate and maintain nonconforming product from finished product inventory for determining product final disposition.\nWe reviewed your firm’s response and concluded that it is not adequate. CAPA-25-009 was provided to address control of non-conforming product. While this CAPA acknowledges the lack of a quarantine area and product non-conformance issues and proposes establishing a dedicated quarantine area with personnel retraining on SOP-022 (Control of Nonconformances), it lacks essential elements including specific corrective actions for each non-conformance type (i.e., unlabeled bottles, expired products, incorrect components, leaking bottles), preventive measures to avoid recurrence, and how ongoing compliance with SOP-022 will be ensured, including specific actions for implementing and maintaining the quarantine area, and establishing a plan for measuring corrective action effectiveness.\nUDI Labeling\nThe inspection revealed that your products would be misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the products was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and package bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Inverness Home Ear Piercing Kit, Inverness Ear Care Solution (0.09%), and Inverness Ear Care Antiseptic (0.12%) products do not bear such a UDI.\nSpecifically, the labels for the Inverness Home Ear Piercing Kit, Inverness Ear Care Solution (0.09%), and Inverness Ear Care Antiseptic (0.12%) products do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology on the label (see 21 CFR 801.40(a)(2)).\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm provided CAPA-25-014, which promises to establish UDIs and update all labels by June 13, 2025. In addition, your firm provided evidence of acquiring DIs for Ear Care Solution, Ear Care Antiseptic, Inverness Disposable Nose Piercing Instrument, and Inverness Reusable Ear Piercing Instruct from GS1. However, your firm has not provided information about the design of the new labels and examples that include valid UDIs.\nSubmitting Required Information to GUDID\nIn addition, the Inverness Home Ear Piercing Kit, Inverness Ear Care Solution (0.09%), and Inverness Ear Care Antiseptic (0.12%) products are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these products. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to these products with the intent that they be commercially distributed without any subsequent replacement or modification of the label. Richline Group, Inc. is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these products.\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\nWe reviewed your firm’s response and concluded that it is not adequate. Though CAPA-25-014 mentions FDA 483 Observation 16 regarding GUDID reporting, the analysis, root cause, and solution do not address the need for GUDID reporting.\nMedical Device Reporting (MDR)\nWe recommend that your firm establish an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports, so that your firm can comply with 21 CFR 803.12(a). FDA verified that, as of June 11, 2025, your firm does not have such an account. Information about the ESG can be found at: How to Enroll in eMDR Program | FDA\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your products or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Melissa Michurski, Assistant Director, at CDRHEnforcement@fda.hhs.gov. Refer to CMS # 712818 when replying. If you have any questions about the contents of this letter, please contact Salvatore Randazzo, Compliance Officer, at 407-475-4712 or salvatore.randazzo@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","The Richline Group, Inc.","richline-group-inc-712818-08252025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frichline-group-inc-712818-08252025","2026-10-26T08:09:49.623729+00:00","2025-09-23","712818","Medical Devices","David E. Radcliffe","2026-08-19T16:18:08.357+00:00","VIA Electronic Mail","2025-08-25",4,{"510k":101,"classification":102,"enforcement":103,"event":104,"event_backfill":105,"pma":106,"warning_letter":107},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]